- Home
- CHRS vs NEOV Comparison
CHRS vs NEOV Comparison
Compare CHRS & NEOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- NEOV
- Stock Information
- Founded
- CHRS 2010
- NEOV 2018
- Country
- CHRS United States
- NEOV United States
- Employees
- CHRS 235
- NEOV N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- NEOV Industrial Machinery/Components
- Sector
- CHRS Health Care
- NEOV Miscellaneous
- Exchange
- CHRS Nasdaq
- NEOV Nasdaq
- Market Cap
- CHRS 134.4M
- NEOV 181.8M
- IPO Year
- CHRS 2014
- NEOV N/A
- Fundamental
- Price
- CHRS $1.16
- NEOV $3.32
- Analyst Decision
- CHRS Strong Buy
- NEOV Strong Buy
- Analyst Count
- CHRS 4
- NEOV 1
- Target Price
- CHRS $5.38
- NEOV $7.50
- AVG Volume (30 Days)
- CHRS 2.4M
- NEOV 314.7K
- Earning Date
- CHRS 03-12-2025
- NEOV 02-11-2025
- Dividend Yield
- CHRS N/A
- NEOV N/A
- EPS Growth
- CHRS N/A
- NEOV N/A
- EPS
- CHRS N/A
- NEOV N/A
- Revenue
- CHRS $304,340,000.00
- NEOV $2,471,178.00
- Revenue This Year
- CHRS $2.47
- NEOV $85.10
- Revenue Next Year
- CHRS N/A
- NEOV $281.25
- P/E Ratio
- CHRS N/A
- NEOV N/A
- Revenue Growth
- CHRS 44.19
- NEOV N/A
- 52 Week Low
- CHRS $0.66
- NEOV $0.63
- 52 Week High
- CHRS $2.87
- NEOV $6.11
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- NEOV 37.59
- Support Level
- CHRS $1.03
- NEOV $3.15
- Resistance Level
- CHRS $1.39
- NEOV $3.85
- Average True Range (ATR)
- CHRS 0.14
- NEOV 0.33
- MACD
- CHRS -0.03
- NEOV -0.05
- Stochastic Oscillator
- CHRS 14.04
- NEOV 18.12
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.